In 2019, nearly 300,000 deaths in India were due to AMR. Over 1 million deaths were linked to drug resistance, making infections more chall...

Researchers have developed a promising class of antibiotics targeting Carbapenem-resistant Acinetobacter baumannii (CRAB), a bacterium resi...

WCK 5222 is a drug, which is entirely a new class of antibiotic known as "β-lactam ENHANCER", and is targeted for treatment of hospitalised...

Natural products from microbes and plants are the biggest resource for drug discovery.

Clinton, 75, was admitted to the University of California Irvine Medical Center on Tuesday evening for a non-COVID-related infection, Angel...

The CPSEs which are under consideration for closure/ under litigation are Hindustan Fluorocarbon Ltd (HFL), Scooters India, Bharat Pumps & ...

CARB-X was formed two years ago as a public-private partnership to tackle the rising menace of antibiotic resistance.

When a patient has a bacterial TB infection, they may be prescribed an antibiotic.

As a woman dies in the US from a superbug infection likely caught in India, four domestic companies are taking up the cudgels in the area o...

"She is in excellent mental condition," said her physician, four days after the Democratic nominee nearly collapsed during the 15th anniver...

Big Pharma is creeping back into development of new antibiotics after decades of largely ignoring the business due to the scant rewards off...

Sources close to the transaction have indicated that Sun Pharma has already bid for US OTC Market listed Insite Vision for Rs 300 cr.

Tuberculosis continues to be a global pandemic, second only to AIDS as the greatest single-agent killer in the world.

Researchers, including one of Indian-origin, have developed a new molecule that may treat multi-drug resistant tuberculosis and even HIV in...

The drug combination, known as PaMZ, killed more bacteria than standard treatment and was effective in treating drug-resistant tuberculosis.

Mumbai-based drug major Nicholas Piramal India (NPIL) is in talks with private equity funds for the sale of a ‘small’ stake in its research...

Nicholas Piramal announced on Monday that it had received approval from the USFDA to start clinical trials on humans for its new cancer dru...